The correct spelling of the term "v Ki ras Oncogenes" is often confusing due to its complex pronunciation. The IPA phonetic transcription for this term is /viː kaɪ ræs ˈɒŋkədʒiːnz/. The "v" represents the viral origin of the oncogenes, while "Ki" stands for Kirsten. "Ras" refers to the human gene that the oncogene is derived from, and "Oncogenes" represent the fact that these genes have the potential to induce tumor formation. Proper spelling and pronunciation are crucial in scientific research to ensure accurate communication and understanding of scientific concepts.
v Ki ras Oncogenes, also known as KRAS oncogenes, refers to a family of oncogenes that are commonly associated with the development and progression of a variety of human cancers, particularly lung, colorectal, and pancreatic cancer. The "v" in the name stands for viral, as these oncogenes were originally discovered in retroviruses, specifically the Kirsten murine sarcoma virus.
KRAS oncogenes are a type of mutated gene found in normal cells that have undergone specific alterations, causing them to promote uncontrolled cell growth and proliferation. Mutations in the KRAS gene result in the production of a defective KRAS protein, which disrupts the normal regulation of cell division and leads to the formation of tumor cells.
The KRAS oncogenes belong to the larger RAS gene family, which plays a crucial role in transmitting signals related to cell growth and division. Mutations in KRAS oncogenes are notorious for rendering cancer cells resistant to certain therapies, making them particularly challenging to target and treat.
Due to their involvement in numerous cancer types and their resistance to conventional treatments, KRAS oncogenes have become a significant focus of cancer research. Investigating the mechanisms by which KRAS mutations contribute to cancer development and progression is crucial for the development of effective targeted therapies aimed at blocking their signaling pathways and inhibiting tumor growth.